GRE2811

GRE2811 is a small molecule Janus kinase (JAK) inhibitor currently under development by Grey Matter Pharma for the treatment of alopecia (hair loss). As a topical therapeutic candidate, GRE2811 is designed to inhibit the JAK-STAT signaling pathway locally within the scalp, thereby reducing the inflammatory response and autoimmune attack on hair follicles that characterizes conditions like alopecia areata. By utilizing a topical route of administration, the drug aims to achieve therapeutic concentrations at the site of hair loss while minimizing the systemic side effects often associated with oral JAK inhibitors. GRE2811 is part of a broader dermatology-focused pipeline at Grey Matter Pharma targeting various inflammatory skin disorders.

Other names

GRE2811GRE-2811GRE 2811